Literature DB >> 11498307

Vaccines for the prevention of HIV-1 disease.

J R Mascola1, G J Nabel.   

Abstract

Clinical investigation in humans and experimental lentivirus infection in nonhuman primates have advanced our understanding of immune responses that control HIV-1 disease. Recently, immunization approaches in macaques have shown that the immune response can control viremia and improve clinical outcome. When such vaccine strategies are formulated to be similarly immunogenic in humans, they could form the basis for the development of candidate AIDS vaccines that would prevent infection, suppress progression to disease or reduce HIV-1 transmission in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498307     DOI: 10.1016/s0952-7915(00)00246-6

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  21 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 2.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

3.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

Review 4.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Authors:  Florence M Brunel; Michael B Zwick; Rosa M F Cardoso; Josh D Nelson; Ian A Wilson; Dennis R Burton; Philip E Dawson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

8.  Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri.

Authors:  Jong-Hyun Kim; Hae-Jin Sohn; Jinyoung Lee; Hee-Jong Yang; Yong-Joon Chwae; Kyongmin Kim; Sun Park; Ho-Joon Shin
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

Review 9.  Non-human primate models of T-cell reconstitution.

Authors:  Janko Nikolich-Zugich
Journal:  Semin Immunol       Date:  2007-11-19       Impact factor: 11.130

10.  Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

Authors:  A Reyes-Sandoval; J C Fitzgerald; R Grant; S Roy; Z Q Xiang; Y Li; G P Gao; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.